Pharmacological modulation of insulin resistance and hyperinsulinemia in polycystic ovary syndrome: The emerging role

Endocrinologist

Volumn 8, Issue 6, 1998, Pages 418-424

  Verma, Subodh ^a,b   Mather, Kieren ^a   Dumont, Aaron S ^a   Anderson, Todd J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ANDROGEN; CATECHOLAMINE; DIAZOXIDE; FOLLITROPIN; INHIBIN; INSULIN; INSULIN RECEPTOR; LUTEINIZING HORMONE; METFORMIN; OCTREOTIDE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; TROGLITAZONE;

ANDROGEN SYNTHESIS; ANOVULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; OBESITY; OVARY POLYCYSTIC DISEASE; REVIEW;

EID: 0031797076     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-199811000-00005     Document Type: Review

References (49)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
2. Ferrannini E, Natli A: Essential hypertension, metabolic disorders and insulin resistance. Am Heart J 1991; 121: 1274-82.
3. Bhanot S, McNeill JH: Insulin and hypertension: a causal relationship? Cardiovasc Res 1996; 31: 212-21.
4. Frank S: Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61.
5. Poison DW, Wadsworth J, Adams J, Franks S: Polycystic ovaries-a common finding in normal women. Lancet 1988; 1: 870-2.
6. Nestler JE: Suppression of ovarian androgen biosynthesis: reduction of circulating insulin. In Androgen Excess Disorders in Women, edited by Azziz R, Nestler JE, Dewailly D. Philadelphia, Lippincott-Raven Publishers, 1997; pp. 727-35.
7. Nestler JE: Insulin and ovarian androgen excess. In Androgen Excess Disorders in Women, edited by Azziz R, Nestler JE, Dewailly D. Philadelphia, Lippincott-Raven Publishers, 1997; pp. 473-83.
8. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
9. Dunaif A, Hoffman AR: Insulin resistance and hyperandrogenism: clinical syndromes and possible mechanisms. In Biorhythms and Stress in the Physiopathology of Reproduction, edited by Panchert P, Zichella L. Washington, DC, Hemisphere Publishing Company, 1988; pp. 293-317.
10. Prelevic GM: Insulin resistance in polycystic ovary syndrome. Curr Opin Obstet Gynecol 1997; 9: 193-201.
11. The Merck Manual of Diagnosis and Treatment, 16th edition, Merck Research Laboratories, NJ, 1992.
12. Dewailly D, Cortet-Rudelli C, Deroubaix-Allard D: Definition, clinical manifestations and prevalence of PCOS. In Androgen Excess Disorders in Women, edited by Azziz R, Nestler JE, Dewailly D. Philadelphia, Lippincott-Raven Publishers, 1997; pp. 259-68.
13. Female genital system and breast. In Basic Pathology, 6th edition, edited by Kumar V, Cotran RS, Robbins SL. Philadelphia, W.B. Sauders Company, 1997; pp. 597-636.
14. Giudice LC: Role of insulin like growth factors (IGF) and IGF binding proteins in PCOS. In Androgen Excess Disorders in Women, edited by Azziz R, Nestler JE, Dewailly D. Philadelphia, Lippincott-Raven Publishers, 1997; pp. 507-18.
15. Pasquali R: The endocrine impact of obesity in eumenorrheic women. In Androgen Excess Disorders in Women, edited by Azziz R, Nestler JE, Dewailly D. Philadelphia, Lippincott-Raven Publishers, 1997; pp. 455-61.
16. Dale PO, Tanbo T, Vaaler S, Abyholm T: Body weight, hyperinsulinemia and gonadotropins in the polycystic ovary syndrome: evidence of two distinct populations. Fertil Steril 1992; 58: 487-91.
17. Bringer J, Lefobvre P, Boulet F, et al.: Body composition and regional fat distribution in polycystic ovary syndrome. Relationship to hormonal and metabolic profiles. Ann NY Acad Sci 1993; 687: 115-23.
18. Dunaif A: Insulin resistance and ovarian hyperandrogenism. Endocrinologist 1992; 2: 248-60.
19. Dewailly D, Duhamel A, Robert Y, et al.: Interrelationship between ultrasonography and biology in the diagnosis of polycystic ovary syndrome. Ann NY Acad Sci 1993; 687: 206-16.
20. Richards GE, Cavallo A, Meyer WJ, et al.: Obesity, acanthosis nigricans, insulin resistance and hyperandrogenemia: pediatric perspective and natural history. J Pediatr 1985; 107: 893-7.
21. Moller DE, Flier JS: Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans and the polycystic ovary syndrome (Type A insulin resistance). N Engl J Med 1988; 319: 1526-9.
22. Barbieri RL, Makris A, Randall RW, Daniels G, Kristner RW, Ryan RJ: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62: 904-10.
23. Cara JF, Rosenfield RL: Insulin-like growth factor I and insulin potentiate luteinizing hormone induced androgen synthesis by rat ovarian thecal cells. Endocrinology 1988; 123: 733-9.
24. DeClue TJ, Shah SC, Marchese M, Malone JI: Insulin resistance and hyperinsulinemia induce hyperandrogenism in young Type B insulin resistant females. J Clin Endocrinol Metab 1991; 72: 1308-11.
25. Nestler JE, Romero G, Huang LC, Zhang C, Larner J: Insulin mediators are the signal transduction system responsible for insulin's actions on human placental steroidogenesis. Endocrinology 1991; 129: 2951-6.
26. Romero G, Garmey JC, Veldhuis JD: The involvement of inositol phosphoglycan mediators in the modulation of steroidogeneis by insulin and insulin like growth factor-I. Endocrinology 1993; 132: 1561-8.
27. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome. N Engl J Med 1996; 335: 617-23.
28. Adashi EY, Hsueh AJW, Yen SSC: Insulin enhancement of luteinizing hormone and follicle stimulating hormone release by cultured pituitary cells. Endocrinology 1981; 108: 1441-9.
29. Berga SL, Guzick DS, Winters SJ: Increased luteinizing hormone and α-subunit secretion in women with hyperandrogenic anovulation. J Clin Endocrinol Metab 1993; 77: 895-901.
30. Plymate S: Regulation of serum sex hormone binding globulin in PCOS. In Androgen Excess Disorders in Women, edited by Azziz R, Nestler JE, Dewailly D. Philadelphia, Lippincott-Raven Publishers, 1997; pp. 497-505.
31. Pasquali R, Casimirri F, Venturoli S, et al.: Body fat distribution has weight independent effects on clinical, hormonal and metabolic features of polycystic ovary disease. Metabolism 1994; 43: 706-13.
32. Sharp P, Kiddy D, Reed M, Anyaoku V, Johnston D, Franks S: Correlation of plasma insulin and insulin like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clin Endocrinol 1991; 35: 253-7.
33. Crave J, Lejeune H, Brebant C, Baret C, Pugeat M: Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid binding globulins by human hepatoblastoma (Hep G2) cells. J Clin Endocrinol Metabol 1995; 80: 1283-9.
34. Hoop RC, Plymate SR: Regulation of SHBG gene expression by steroid and peptide hormones. VIII International Congress of Hormonal Steroids, The Hague, The Netherlands, 1990.
35. Nestler J, Powers L, Matt D, et al.: A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-9.
36. Kahn CR: Insulin action, diabetogenes and the cause of type II diabetes. Diabetes 1994; 43: 1066-1084.
37. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74.
38. Dunaif A, Xia J, Book C, Schenker E, Tang Z: Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-10.
39. Lanzone A, Fulghesu AM, Cucinelli F, Ciampelli M, Caruso A, Mancuso S: Evidence of a distinct derangement of opiod tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion. J Clin Endocrinol Metab 1995; 80: 3501-6.
40. Kiddy DS, Hamilton Fairley D, Seppala M, et al.: Diet induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin like growth factor-I. Clin Endocrinol 1989; 31: 757-63.
41. Kiddy DS, Hamilton-Fairley D, Bush A, et al.: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36: 105-11.
42. DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean non insulin dependent diabetic subjects. J. Clin Endocrinol Metab 1991; 73: 1294-301.
43. Nestler J, Jakubowicz DJ: Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 1997; 82: 4075-9.
44. Valazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-54.
45. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876-80.
46. Dunaif A, Scott D, Finegood D, Quintana B, Whitecomb R: The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299-306.
47. Nestler JE, Barlascini CO, Matt DW, et al.: Supression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989; 68: 1027-32.
48. Prelevic GM, Wutzburger MI, Balint-Peric L, Nesic JS: Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990; 336: 900-3.
49. Fulghesu AM, Lanzone A, Andreani CL, Pierro E, Caruso A, Mancuso S: Effectiveness of somatostatin analogue in lowering luteinizing hormone and insulin stimulated secretion in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 1995; 64: 703-8.